Insider Selling: BioDelivery Sciences International, Inc. (BDSI) Insider Sells 6,905 Shares of Stock, Report finds

Insider Selling: BioDelivery Sciences International, Inc. (BDSI) Insider Sells 6,905 Shares of Stock, Report finds

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) insider Niraj Vasisht sold 6,905 shares of the stock in a transaction on Monday, January 30th. The shares were sold at an average price of $1.91, for a total value of $13,188.55. Following the sale, the insider now owns 178,727 shares in the company, valued at approximately $341,368.57. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) traded up 1.282% during mid-day trading on Wednesday, reaching $1.975. The company’s stock had a trading volume of 354,792 shares. The firm’s 50 day moving average price is $1.85 and its 200 day moving average price is $2.19. BioDelivery Sciences International, Inc. has a 12-month low of $1.50 and a 12-month high of $4.39. The stock’s market cap is $106.88 million.

A number of institutional investors have recently added to or reduced their stakes in the company. Ameriprise Financial Inc. bought a new position in BioDelivery Sciences International during the second quarter worth $2,104,000. Bank of Montreal Can raised its position in BioDelivery Sciences International by 2.2% in the third quarter. Bank of Montreal Can now owns 713,805 shares of the specialty pharmaceutical company’s stock worth $1,927,000 after buying an additional 15,515 shares during the period. Baker BROS. Advisors LP bought a new position in BioDelivery Sciences International during the third quarter worth $567,000. Searle & CO. acquired a new stake in BioDelivery Sciences International during the third quarter worth approximately $455,000. Finally, Tiverton Asset Management LLC increased its stake in BioDelivery Sciences International by 206.1% in the third quarter. Tiverton Asset Management LLC now owns 180,417 shares of the specialty pharmaceutical company’s stock worth $487,000 after buying an additional 121,468 shares in the last quarter. 50.95% of the stock is currently owned by institutional investors.

Several research firms recently weighed in on BDSI. Zacks Investment Research lowered BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Wednesday. FBR & Co set a $5.00 price target on BioDelivery Sciences International and gave the company a “buy” rating in a report on Thursday, February 2nd. Cantor Fitzgerald set a $3.00 price target on BioDelivery Sciences International and gave the company a “hold” rating in a report on Tuesday, January 17th. Finally, Roth Capital set a $6.00 price target on BioDelivery Sciences International and gave the company a “buy” rating in a report on Monday, December 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. BioDelivery Sciences International currently has a consensus rating of “Hold” and an average price target of $5.00.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Related posts

Leave a Comment

Insider Selling: BioDelivery Sciences International, Inc. (BDSI) Insider Sells 6,905 Shares of Stock

Insider Selling: BioDelivery Sciences International, Inc. (BDSI) Insider Sells 6,905 Shares of Stock

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) insider Niraj Vasisht sold 6,905 shares of the stock in a transaction on Monday, January 30th. The shares were sold at an average price of $1.91, for a total value of $13,188.55. Following the sale, the insider now owns 178,727 shares in the company, valued at approximately $341,368.57. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) traded up 1.282% during mid-day trading on Wednesday, reaching $1.975. The company’s stock had a trading volume of 354,792 shares. The firm’s 50 day moving average price is $1.85 and its 200 day moving average price is $2.19. BioDelivery Sciences International, Inc. has a 12-month low of $1.50 and a 12-month high of $4.39. The stock’s market cap is $106.88 million.

A number of institutional investors have recently added to or reduced their stakes in the company. Ameriprise Financial Inc. bought a new position in BioDelivery Sciences International during the second quarter worth $2,104,000. Bank of Montreal Can raised its position in BioDelivery Sciences International by 2.2% in the third quarter. Bank of Montreal Can now owns 713,805 shares of the specialty pharmaceutical company’s stock worth $1,927,000 after buying an additional 15,515 shares during the period. Baker BROS. Advisors LP bought a new position in BioDelivery Sciences International during the third quarter worth $567,000. Searle & CO. acquired a new stake in BioDelivery Sciences International during the third quarter worth approximately $455,000. Finally, Tiverton Asset Management LLC increased its stake in BioDelivery Sciences International by 206.1% in the third quarter. Tiverton Asset Management LLC now owns 180,417 shares of the specialty pharmaceutical company’s stock worth $487,000 after buying an additional 121,468 shares in the last quarter. 50.95% of the stock is currently owned by institutional investors.

Several research firms recently weighed in on BDSI. Zacks Investment Research lowered BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Wednesday. FBR & Co set a $5.00 price target on BioDelivery Sciences International and gave the company a “buy” rating in a report on Thursday, February 2nd. Cantor Fitzgerald set a $3.00 price target on BioDelivery Sciences International and gave the company a “hold” rating in a report on Tuesday, January 17th. Finally, Roth Capital set a $6.00 price target on BioDelivery Sciences International and gave the company a “buy” rating in a report on Monday, December 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. BioDelivery Sciences International currently has a consensus rating of “Hold” and an average price target of $5.00.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Related posts

Leave a Comment